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Summary (Word count: 250) 
Background:Anti-tumor necrosis factor-α (TNF-α) is used for the treatment of severe cases of 
inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). 
However, one-third of the patients do not respond to the treatment. We have previously investigated 
whether single nucleotide polymorphisms (SNPs) in genes involved in inflammation were 
associated with response to anti-TNF therapy among patients with CD or UC.  
Aim:A new cohort of patients was established for replication of the previous findings and to
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Methods:Fifty-three SNPs assessed previously in cohort 1 (482CD and 256UC patients) were 
genotyped in cohort 2 (587CD and 458UC patients). The results were analyzed using logistic 
regression (adjusted for age and gender). 
Results:Ten SNPs were associated with anti-TNF response either among patients with CD 
(TNFRSF1A(rs4149570)(OR:1.92,95%CI:1.02-3.60,p=0.04), 
IL18(rs187238)(OR:1.35,95%CI:1.00-1.82,p=0.05), and JAK2(rs12343867)(OR:1.35,95%CI:1.02-
1.78,p=0.03)), UC (TLR2(rs11938228)(OR:0.55,95%CI:0.33-0.92,p=0.02), 
TLR4(rs5030728)(OR:2.23,95%CI:1.24-4.01,p=0.01) and (rs1554973)(OR:0.49,95%CI:0.27-
0.90,p=0.02), NFKBIA(rs696)(OR:1.45,95%CI:1.06-2.00,p=0.02), and 
NLRP3(rs4612666)(OR:0.63,95%CI:0.44-0.91,p=0.01)) or in the combined cohort of patient with 
CD and UC (IBD) (TLR4(rs5030728)(OR:1.46,95%CI:1.01-2.11,p=0.04) and 
(rs1554973)(OR:0.80,95%CI:0.65-0.98,p=0.03), NFKBIA(rs696)(OR:1.25,95%CI:1.01-
1.54,p=0.04), NLRP3(rs4612666)( OR:0.73,95%CI:0.57-0.95,p=0.02), 
IL1RN(rs4251961)(OR:0.81,95%CI:0.66-1.00,p=0.05), IL18(rs1946518)(OR:1.24,95%CI:1.01-
1.53,p=0.04), and JAK2(rs12343867)(OR:1.24,95%CI:1.01-1.53,p=0.04)). 
Conclusion:The results support that polymorphisms in genes involved in the regulation of the 
NFκB pathway (TLR2, TLR4, and NFKBIA), the TNF-α signaling pathway (TNFRSF1A), and other 
cytokine pathways (NLRP3, IL1RN, IL18, and JAK2) were associated with response to anti-TNF 
therapy. Our multi-SNP model predicted response rate of more than 82% (in 9% of the CD patients) 
and 75% (in 15% of the UC patients), compared to 71% and 64% in all CD and UC 






Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are 
characterized by a dysregulated inflammatory response 1. The diseases can be of great importance 
to the affected persons - in terms of reduced quality of life - and for the society - in terms of cost of 
lost labour due to sickness, treatment and medicine. Anti-tumor necrosis factor-α (anti-TNF) are 
therapeutic antibodies that block the binding of the pro-inflammatory cytokine tumor necrosis 
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also lead to apoptosis by binding to transmembrane TNF-α 3-5. Anti-TNF is used for the treatment 
of severe cases of IBD, but approximately one-third of the patients benefit minimally or not at all 
from the treatment 6,7
Pathogen-Associated Molecular Patterns (PAMPs) such as bacterial or viral DNA, flagellin or 
lipopolysaccharide (LPS) can bind to the membrane-bound Toll-like receptors (TLRs) leading to 
increased inflammation mediated by increased synthesis of a number of pro-inflammatory cytokines. 
PAMPs bound by the TLRs initiate a kinase cascade. This kinase cascade ultimately activates the 
IKK-complex, which phosphorylates and degrades the NFκB inhibitor IκBα 
. 
8. The released NFκB 
is shuttled from the cytosol to the nucleus where it acts as a transcription factor which initiates 
expression of pro- and anti-inflammatory cytokines 9. One of the pro-inflammatory cytokines 
activated by NFκB is TNF-α, which feedback stimulates NFκB by binding to TNF receptors 
(TNFR1 or TNFR2) resulting in a kinase cascade similar to, but distinct from, the canonical 
pathway induced by TLRs 8
PAMPs may also be recognized by Nod-like receptors (NLRs), which are intracellular receptors. 
.
NLRP3 is a subunit of the inflammasome protein complexes and can activate pro- IL-1β and IL-18 
which in turn can activate the synthesis of other cytokines 10,11
By using a candidate gene approach of biological functional single nucleotide polymorphisms 
(SNPs) in selected pathways we have previously identified SNPs in genes involved in inflammation 
associated with response to anti-TNF therapy among patients with CD or UC 
. 
12,13. We have now 
established a new cohort of patients with CD or UC treated with anti-TNF. The aim of the present 
study was to replicate our previous results in the new cohort, and to i entify new SNPs associated 
with anti-TNF response using the increased statistical power of the combined cohort. The 
replication of the results in independent cohorts 
 
is the first step on the road to identify the biological 
pathways underlying treatment response and to develop alg rithms predicting treatment effect for 
use in the clinic. 
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This study was a replication of a previous study consisting of 482 CD and 256 UC Danish patients 
treated with anti-TNF (cohort 1) 12,13. For this study, a replication cohort (cohort 2) of anti-TNF 
treated Danish patients with CD or UC was established. The cohort 2 was established using the 
same approach as was used for establishing cohort 1 12,13. Screening for Mycobacterium 
tuberculosis (TB) infection is routinely performed in Denmark before initiation of treatment with 
anti-TNF treatment. For the cohort 2, left over blood clots after whole blood analysis for TB were 
collected from 01.09.2009 to 31.01.2014 from patients screened for tuberculosis at Statens Serum 
Institut (Copenhagen, Denmark); the Department of Respiratory Diseases B and the Department of 
Clinical Microbiology, Aarhus University Hospital (Aarhus, Denmark); the Department of Clinical 
Biochemistry, Herlev and Gentofte Hospital (Hellerup, Denmark); the Department of Biochemistry, 
Hospital of Lillebaelt (Vejle, Denmark); and the Department of Biochemistry, Hospital of Slagelse 
(Slagelse, Denmark). Patients with intestinal diseases (ICD-10 code K50-K63) were identified by 
linking the unique personal identification number of Danish citizens (CPR-number) from each 
blood sample with the National Patient Registry. Patient records from 23 medical departments were 
examined and 587 CD and 458 UC patients treated with anti-TNF were identified. Figure 1 shows 
how cohort 2 was established. Patients on infliximab were routinely treated intravenously at the 
hospital whereas adalimumab was self-administered by the patients 14,15
In this retrospective study treatment efficacy was assessed using the simple clinical 3-step scale 
. 
16-20
The medical doctors reviewing the patient records regarding treatment response to anti-TNF were 
blinded to genotyping results. Clinical and demographic characteristics of the patients w th CD, UC, 
and IBD for the combined cohort (cohort 1 and 2 combined) are shown in Table 1, and data for 
cohort 1 and cohort 2 are shown in Supporting Table 1 and 2, respectively. 
 
reflected the best response within 26 weeks after initiation. Patients with CD or UC with luminal 
disease were categorised as having: (A) no response, meaning no improvement or worsening of 
symptoms; (B) partial response, meaning some improvement of symptoms or reduction of steroid 
dose without worsening of symptoms; (C) response, meaning absence or almost absence of all 
clinical symptoms without increasing the steroid dose. Patients with fistulising CD were categorised 
as having: (A) no response, meaning no improvement or worsening of symptoms; (B) partial 
response, meaning reduced secretion or discomfort from fistulas or closure of one or sme of the 
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Biologically functional SNPs in genes involved in the NFκB, the TNF-α, and other cytokine 
pathways previously assessed in cohort 1 were genotyped in cohort 2 12,13. Most of the SNPs 
assessed have previously been examined by luciferase assay, enzyme-link d immunosorbent assay 
(ELISA), reverse transcriptase PCR, electrophoretic mobility shift assay (EMSA) or in flow 
cytometry assay to have a biological function which either increased or reduced gene activity 12,13. 
A list of all SNPs studied, and the genotype distribution among patients with CD, UC, and IBD are 
presented in Supporting Table 3-5, respectively. Minor allele frequencies are presented in 
Supporting Table 6. DNA extraction (Maxwell 16 LEV Blood DNA Kit; Promega, Madison, WI, 
USA) was performed as described by Bank et al. 21
 
. Competitive Allele-Specific Polymerase chain 
reaction (KASP™), an end-point PCR technology, was used by LGC Genomics for genotyping 
(LGC Genomics, Hoddesdon, United Kingdom) (http://www.lgcgenomics.com/). As a quality 
control, all SNPs were replicated in 192 randomly selected samples (two 96-ell plates minus two 
negative controls), yielding >99% identical genotypes. The average call rate for all SNPs was > 
97%. 
Power calculations  
The Genetic Power Calculator was utilized for power analysis of discrete traits 22
The cohort 1, cohort 2, and the combined cohorts had more than 80% chance of detecting a 
dominant effect with an odds ratio (OR) of 1.5, 1.4, and 1.3, respectively. 
. The ‘high-risk 
allele frequency’ was set to 0.10, ‘prevalence’ was set to 0.33, D-prime was set to 1, type I error 
rate was set to 0.05, and number of cases and control:case (responders:non&partial-responders) 
ratio was based on the actual distributions in the study group (found in Table 1).  
 
Statistical analysis 
Logistic regression adjusted for age at treatment and gender was used to compare genotypes 
between (a) responders versus non-responders; (b) responders versus non- and partial-responders to 
anti-TNF therapy among patients with CD, UC, and IBD (Supporting Table 7 and 8, respectively). 
Odds ratio unadjusted (crude) and adjusted for age at treatment, gender and smoking status between 
(a) responders versus non-responders; (b) responders versus non- and partial-responders to a ti-
TNF therapy among patients with CD, UC, and IBD were included in Supporting Table 9-12. A 
summary of SNPs associated with response to anti-TNF therapy and the biological effect of the 
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A chi-square test or unpaired t-test was used to test for statistically significant difference in 
response between patients with CD and UC and for difference in secondary parameters (gender, age, 
location, smoking, concomitant medication, CRP, and F-cal) between responders and non-
responders (Table 1) and for haplotype analysis (Supporting Table 13-15). 







Study population  
The clinical and demographic characteristics of the anti-TNF treated patients with CD (482 and 587 
from cohort 1 and 2, respectively) and UC (256 and 458 from cohort 1 and 2, respectively) as well 
as CD and UC combined (IBD) are shown in Table 1. The percentage of of patients treated with 
infliximab, and adalimumab were 87%, and 13%, respectively. In the combined cohort, more 
females (16%) than males (9%) were non-responders among patients with CD (OR: 1.92, 95% CI: 
1.31-2.82, p = 0.001). Young age at treatment was associated with beneficial response (p = 0.0007) 
among patients with CD. Never smoking was associated with beneficial response (OR: 2.27, 95% 
CI: 1.29-3.99, p = 0.005) among patients with CD. 
Furthermore, the rate of non-response was higher among patients with UC than CD (23% (167 
patients) and 13% (140 patients), respectively (OR: 1.98, 95% CI: 1.54-2.55, p = 0.0001)). 
 
Polymorphisms associated with response in CD 
In the combined cohort (cohort 1 and cohort 2 combined), the homozygous variant genotype of 
TNFRSF1A -609 G>T (rs4149570) (OR: 1.92, 95% CI: 1.02-3.60, p = 0.04) and the combined 
homozygous and the heterozygous variant genotypes of IL18 -137 G>C (rs187238) (OR: 1.35, 95% 
CI: 1.00-1.82, p = 0.047) and JAK2 T>C (rs12343867) (OR: 1.35, 95% CI: 1.02-1.78, p = 0.03) 
were associated with beneficial response among patients with CD (Supporting Table 7 and 8). 
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In the combined cohort, the homozygous variant genotype of TLR2C>A (rs11938228) (OR: 0.55, 
95% CI: 0.33-0.92, p = 0.02) and TLR4 T>C (rs1554973) (OR: 0.49, 95% CI: 0.27-0.90, p = 0.02) 
and the combined homozygous and the heterozygous variant genotypes of NLRP3C>T (rs4612666) 
(OR: 0.63, 95% CI: 0.44-0.91, p = 0.01) were associated with non-response among patients with 
UC. The homozygous variant genotype of TLR4 G>A (rs5030728) (OR: 2.23, 95% CI: 1.24-4.01, p 
= 0.01) and the combined homozygous and the heterozygous variant genotypes of NFKBIA 2758 
G>A (rs696) (OR: 1.45, 95% CI: 1.06-2.00, p = 0.02) were associated with beneficial response 
among patients with UC (Supporting Table 7 and 8). 
 
Polymorphisms associated with response in CD and UC combined (IBD) 
In the combined cohort, the homozygous variant genotype of TLR4G>A (rs5030728) (OR: 1.46, 
95% CI: 1.01-2.11, p = 0.04) and the combined homozygous and the heterozygous variant 
genotypes of NFKBIA 2758 G>A (rs696) (OR: 1.25, 95% CI: 1.01-1.54, p = 0.04), JAK2 T>C 
(rs12343867) (OR: 1.24, 95% CI: 1.01-1.53, p = 0.04) and IL18 -607 C>A (rs1946518) (OR: 1.24, 
95% CI: 1.01-1.53, p = 0.04) were associated with beneficial response among patients with IBD. 
The combined homozygous and the heterozygous variant genotypes of TLR4 T>C (rs1554973) (OR: 
0.80, 95% CI: 0.65-0.98, p = 0.03), NLRP3 C>T (rs4612666) (OR: 0.73, 95% CI: 0.57-0.95, p = 
0.02) and IL1RN T>C (rs4251961) (OR: 0.81, 95% CI: 0.66-1.00, p = 0.049) were associated with 
non-response among patients with IBD (Supporting Table 7 and 8). 
SNPs associated with anti-TNF response in CD, UC, or IBD patients and the biological 
interpretation of the associations are summarized in Table 2. A forest plot of the SNPs associated 
with anti-TNF response in CD, UC, or IBD patients is shown in Figure 2. 
 
Haplotype analysis 
Haplotype analysis of TLR2, TLR4, and IL1B are shown in Supporting Table 13-15, respectively. 
No associations were found in the haplotype analysis. 
 
Predictive value  
Sensitivity, specificity, positive (PPV) and negative predictive value (NPV) for risk sum (number of 
alleles) of the SNPs associated with drug response in CD or UC in the combined cohort is shown in 
Table 3 and 4, respectively. For CD, patients with a risk sum of 5 or 4-5 had a chance of 94% 















This article is protected by copyright. All rights reserved 
71% (760/1069) for all CD patients. This value applied to 2% (17/1069) and 9% (92/1069) of the 
CD patients, respectively. Similarly, for UC, patients with a risk sum of 0 or 0-2 had a chance of 
89% (8/9) and 75% (79/105) for being responders to anti-TNF treatment compared to 64% (459/714) 







In this combined study (cohort 1 and 2 combined) 10 of the 53 SNPs assessed in the NFκB pathway 
(TLR2 (rs11938228), TLR4 (rs5030728 and rs1554973), and (NFKBIA (rs696)), the TNF-α pathway 
(TNFRSF1A (rs4149570)), and other pro-inflammatory pathways (IL1RN (rs4251961), IL18 
(rs1946518 and rs187238), NLRP3 (rs4612666), and JAK2 (rs12343867)), were associated with 
response to anti-TNF among patients with CD or UC. In this combined study 3 of the 15 SNPs 
associated with response after adjusting for age and gender in our previous studies of cohort 112,13 
were replicated (TLR4 (rs5030728 and rs1554973) and TNFRSF1A (rs4149570)). Associations with 
response to anti-TNF have previously been found for the TLR2 (rs11938228), IL1RN (rs4251961), 
IL18 (rs1946518), and JAK2 (rs12343867) SNPs in unadjusted analysis or when adjusting for age, 
gender and smoking 12,13
Based on our results we made a predictive model of response to anti-TNF, where we summarised 
the number of alleles (risk sum) of the SNPs associated with response in CD or UC (Table 3-4, and 
Supporting Figure 1-2). Although our predicitive model has limited clinical value as it is, it shows a 
clear trend of treatment response associated with allele count (risk sum) in the polygenetic 
predictive model in both cohort 1 and cohort 2, and in both CD and in UC patients (Supporting 
Table 16-19 and Supporting Figure 3-6). This indicates that with increasing number of SNPs 
associated with response used in the predictive model and with increasing number of pati nts
included, that a clinical useful predictive model for anti-TNF treatment may be achieveable. 
 with the odds ratio in the same direction as in this study of cohort 1 and 2 
combined and adjusted for age and gender. Finally, novel associations were found in the NFκB 
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Hypothesis-free genome wide association studies (GWAS) and the establishment of more cohorts of 
anti-TNF treated patients i  warranted to adequately predict response to anti-TNF for clinical use.  
Genetic studies of other diseases like breast cancer also started out with including a low number of 
patients and identifying few susceptibility SNPs. Now with incrieasing numbers of patients 
included in the studies and a change of focus from single SNP to creating algorithms including 
multiple susceptibility SNPs the models are increasingly getting value for clinical application 23
Most of the SNPs assessed in our study have known biological effects thus allowing a biological 
interpretation of the observed associations based on increased or reduced gene activity as 
summarized in Table 2 and illustrated in Figure 3 
. 
12,13,16,17,24-32. Among patients with CD, the 
association observed for the TNFRSF1A (rs4149570) polymorphism indicates that increased 
expression of the TNF-α receptor 1 33, and thus increased activity of the TNF-α pathway, was 
associated with beneficial response. Furthermore, the association observed for the IL18 (rs187238) 
polymorphism indicates that increased IL-18 expression 34,35 was associated with non-response. In 
addition, the association observed for the JAK2 (rs12343867) polymorphism indicates that 
increased JAK2 expression 36 was associated with non-response. The JAK2 kinase interacts with 
many different membrane receptors including the IFNG, IL12, and IL23 receptor 37,38
Among patients with UC, the association observed for the NFKBIA (IκBα) (rs696) polymorphism 
indicates that reduced NFKBIA expression 
. The 
associations for the IL18 (rs187238) and the JAK2 (rs12343867) polymorphisms both indicate that 
genetically determined high activity ofther cytokine pathways may be able to maintain the 
inflammation even after anti-TNF therapy and result in non-response. 
39 was associated with non-response. IκBα acts as an 
inhibitor of the transcription factor NFκB which can activate many pro-inflammatory cytokines 
including IL-1β 9
The polymorphisms in TLR2 (rs11938228) and TLR4 (rs5030728 and rs1554973) associated with 
response among patients with UC have unknown biological effect but they underscore the 
importance of the NFκB pathway in response to anti-TNF therapy 
. Thus, reduced activity of IκBα increases the activity of other cytokine pathways. 
Again, as among patients with CD, it could be speculated that high activity of other pro-
inflammatory cytokines may be able to maintain the inflammation even after anti-TNF therapy and 
result in non-response. 
40
Furthermore, the association observed for the NLRP3 (rs4612666) polymorphism indicates that 
increased NLRP3 expression 
. 
41 was associated with beneficial response. NLRP3 is involved in the 















This article is protected by copyright. All rights reserved 
results in this study which indicates that increased IL-18 activity was associated with non-response. 
However, NLRP3 can also stimulate apoptosis as well as pyroptosis through activation of 
caspases 42,43. Anti-TNF can induce apoptosis 3-5 and it could be speculated, that anti-TNF has a 
better effect among patients, whose pro-inflammatory secreting cells are genetically determined 
more prone for programmed cell death. In addition, the NLRP3 (rs4612666) polymorphism has also 
been found to be associated with anti-TNF therapy among patients with rheumatoid arthritis 26
In the combined cohort of patient with CD and UC (IBD), the same polymorphisms associated with 
response in CD (JAK2 (rs12343867)) and UC (NFKBIA (rs696), TLR4 (rs5030728 and rs1554973) 
and NLRP3 (rs4612666)) were found. Furthermore, the association observed for the IL18 
(rs1946518) polymorphism indicates that increased IL-18 expression 
.  
34,35,44 was associated with 
non-response. As for the other polymorphism in IL18 (rs187238), associated with response to anti-
TNF among patient with CD, it could be speculated that genetically determined high activity of the 
IL18 pathway may be able to maintain the inflammation even after anti-TNF therapy and result in 
non-response. In addition, the association observed for the IL1RN (rs4251961) (IL-1 receptor 
antagonist (IL-1RA) polymorphism indicates that reduced IL-1RA level 45 was associated with non-
response. IL-1RA can bind to the IL-1β receptor and thereby inhibit IL-1β signaling 45. It could be 
speculated that genetically determined high activity of the IL-1β pathway may be able to maintain 
the inflammation even after anti-TNF therapy and result in non-response. This interpretation is 
supported by another study which has reported an association between the C-allel of rs1143634 in 
IL1B and higher serum IL-1β level and a lower response rate to anti-TNF therapy among patients 
with CD 46
The results of this study should be interpreted with caution and should be evaluated in other cohorts 
of anti-TNF treated patients. In the light of the obtained P-values and the number of statistical tests 
performed, we cannot exclude that some of our positive findings may be due to chance (type I error). 
However, the direction of the odds ratio in all the 10 SNPs associated with response was biological 
plausible when interpretated based on the alleles ffect on increased or reduced gene activity which 
is very unlikely if they were all chance findings (p = 0.001). We cannot exclude that associations 
were not identified due to insufficient statistical power. One of the SNPs associated with response 
in the cohort 1 study but not in this study was the IL6 (rs10499563) polymorphism where the 
combined homozygous and the heterozygous variant genotypes were borderline associated with 
. It could be speculated that some patients who do not respond to anti-TNF therapy may 
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beneficial response among patients with IBD (OR: 1.31, 95% CI: 0.99-1.71, p = 0.05). The variant 
allele has been shown to reduce IL-6 expression 47
A major strength of this study was that this clinically homogeneous and well-characterized cohort 
was rather large including 1783 patients with IBD treated with anti-TNF which gives the cohort 
study more than 80% power to detect an odds ratio of 1.3 assuming a minor allele frequency of 0.10.
Furthermore, the found associations were biologically plausible. In addition, it s well-known that 
patients recruited to clinical trials are selected and may not represent “real” patients. This study 
collected clinical data from patients at 23 large gastroenterological centers at basic and specialized 
hospitals in Denmark. Thus, the patients are representative of Danish patients with severe IBD. 
Althought the collection of patients from the clinical setting may give an advantage in that the 
results may be readily transferable to the clinical setting, a drawback may be the definition of 
response which may be challenging. In this study, we have used the simple clinical 3-step scale to 
assess response, which has been used in other studies as well and it has turned out to be useful 
 which would indicate that patients with 
genetically determined high IL-6-driven inflammatory response were more likely to be non-
responders to anti-TNF therapy. This supports that the activity of other cytokines than TNF-α are 
important predictors for the response to anti-TNF therapy.  
16-20
In conclusion, the results indicate that polymorphisms in genes involved in the regulation of the 
NFκB pathway (TLR2, TLR4, and NFKBIA), the TNF-α signaling pathway (TNFRSF1A), and other 
cytokine pathways (NLRP3, IL1RN, IL18, and JAK2) were associated with response to anti-TNF 
therapy. Overall, the associations in TNFRSF1A, IL1RN and IL18 indicate that patients with 
genetically determined high TNF-driven inflammatory response are most likely to benefit from anti-
TNF therapy while patients with genetically determined high IL-1β or IL-18-driven inflammatory 
response seem to be less likely to benefit from anti-TNF therapy, perhaps because these cytokines 
may be able to maintain the inflammation even after anti-TNF therapy and thus result in non-
response. More studies including larger cohorts and using genome-wide analysis are warranted to 
develop genetic biomarkers to predict response to anti-TNF for use in the clinic. 
. 
Another strength is that a high compliance was ensured in this study as 87% of the patients were 
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Table 1: Clinical and demographic characteristics for the combined Danish cohort (cohort 1 and cohort 2 combined) for anti-tumor necrosis factor alpha (TNF-α) naïve patients with Crohn's disease, ulcerative 
colitis and inflammatory bowel disease treated with anti-TNF. 

































Efficacy - no (%)  
a
 
761 (71) 140 (13) 308 (29) -  459 (64) 167 (23) 255 (36) -  1220 (68) 307 (17) 563 (32) - 
               
Gender  - no (%)               
Male 356 (75) 44 (9) 117 (25)   221 (64) 77 (22) 122 (36)   577 (71) 121 (15) 239 (29)  
Female 405 (68) 96 (16) 191 (32) 8*10
^-4 
 238 (64) 90 (24) 133 (36) 0.72  643 (66) 186 (19) 324 (34) 0.06 
               
Age, years                
Age at treatment, median (range) 33 (3-79) 40 (16-77) 38 (15-77) 7*10
^-4 
 38 (4-84) 37 (15-81) 38 (7-81) 0.68  35 (3-84) 38 (15-81) 38 (7-81) 7*10
^-3 
               
Anti -TNF antibody treatment                
Infliximab 624 (82) 103 (74) 240 (78)   442 (96) 151 (90) 234 (92)   1066 (87) 254 (83) 474 (84)  
Adalimumab 135 (18) 36 (26) 67 (22) 0.03  11 (2) 16 (10) 21 (8) 3*10^
-4 
 146 (12) 52 (17) 88 (16) 0.01 
Golimumab 2 (0) 1 (0) 1 (0) -  6 (1) 0 (0) 0 (0) -  8 (1) 1 (0) 1 (0) - 
               
Loc ation - no (%)               
Ileal (L1)  198 (26) 47 (34) 84 (27) 0.08  - - - -  198 (26) 47 (34) 84 (27) 0.08 
Colonic (L2)  249 (33) 39 (28) 98 (32) 0.28  - - - -  249 (33) 39 (28) 98 (32) 0.28 
Ileocolonic (L3)  263 (35) 43 (31) 97 (31) 0.38  - - - -  263 (35) 43 (31) 97 (31) 0.38 
Data not available 51 (7) 11 (8) 29 (9) -  - - - -  51 (7) 11 (8) 29 (9) - 
               
Location - no (%)               
Proctitis (E1)  - - - -  83 (18) 33 (20) 48 (19) 0.64  83 (18) 33 (20) 48 (19) 0.64 
Left side (E2)  - - - -  144 (31) 56 (34) 83 (33) 0.63  144 (31) 56 (34) 83 (33) 0.63 
Extensive (E3)  - - - -  185 (40) 61 (37) 89 (35) 0.41  185 (40) 61 (37) 89 (35) 0.41 
Data not available - - - -  47 (10) 17 (10) 35 (14) -  47 (10) 17 (10) 35 (14) - 
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Smoking history, at treatment  
– no (%) 
              
Current smoker 192 (25) 37 (26) 85 (28) 0.83  32 (7) 6 (4) 11 (4) 0.13  224 (18) 43 (14) 96 (17) 0.24 
Former smoker 75 (10) 11 (8) 30 (10) 0.53  96 (21) 35 (21) 55 (22) 1.00  171 (14) 46 (15) 85 (15) 0.82 
Never smoker 163 (21) 15 (11) 44 (14) 0.01  91 (20) 35 (21) 52 (20) 0.82  254 (21) 50 (16) 96 (17) 0.22 
Data not available 331 (43) 77 (55) 149 (48) -  240 (52) 91 (54) 137 (54) -  571 (47) 168 (55) 286 (51)  
               
Concomitant medication  – no (%)               
Azathioprine 297 (39) 51 (36) 138 (45) 0.57  138 (30) 47 (28) 73 (29) 0.69  435 (36) 98 (32) 211 (37) 0.32 
5-aminosalicylates 54 (7) 12 (9) 21 (7) 0.60  178 (39) 72 (43) 105 (41) 0.36  232 (19) 84 (27) 126 (22) 0.01 
Glucocorticoids 228 (30) 57 (41) 118 (38) 0.01  228 (50) 87 (52) 128 (50) 0.65  456 (37) 144 (47) 246 (44) 0.02 
Methotrexate 21 (3) 4 (3) 11 (4) 1.00  5 (1) 1 (1) 2 (1) 0.69  26 (2) 5 (2) 13 (2) 0.60 
Antibiotics 35 (5) 12 (9) 28 (9) 0.06  20 (4) 11 (7) 16 (6) 0.30  55 (5) 23 (7) 44 (8) 0.11 
               
C-reactive protein (CRP) and F -
calprotectin – no (%) 
              
> 25% decrease in CRP within 22 

























> 25% decrease in F-cal within 22 
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Table 2: Biological interpretation of the single nucleotide polymorphisms (SNPs) associated with anti-TNF response in Crohn's disease (CD), ulcerative colitis (UC) or inflammatory bowel 
disease (IBD) patients in the combined Danish cohort (cohort 1 and cohort 2 combined).  
Gene Rs-number  Pathway  Model  OR (95% CI) P-value  Effect of minor -allele  Biological interpretation  
Crohn's disease  (CD) 





Increased TNF-α receptor 1 expression was associated with 
beneficial response. This indicates that genetically 
determined high TNF-driven inflammatory response was 
associated with beneficial response. 
  
IL18  rs187238 Cytokines 
 





 and expression in 
PBMC 
35
Reduced IL-18 expression was associated with beneficial 
response. This indicates that genetically determined high 
IL18-driven inflammatory response was associated with non-
response. 
 
JAK2 rs12343867 Cytokines TC or CC 
vs TT 
1.35 (1.02-1.78) 0.03 rs12343867C reduce expression 




Reduced JAK2 expression was associated with beneficial 
response. The JAK2 kinase interacts with many different 




Ulcerative colitis (UC)  
. This indicates that genetically determined high 
activity of other pro-inflammatory pathways was associated 
with non-response. 
TLR2  rs11938228 Pathogen 
recognition 






TLR4  rs5030728 Pathogen 
recognition 





TLR4  rs1554973 Pathogen 
recognition 





NFKBIA  rs696 Pathogen 
recognition 
GA or AA 
vs GG 
1.45 (1.06-2.00) 0.02 2758A increase expression in 





Increased NFKBIA expression was associated with 
beneficial response. IκBα acts as an inhibitor of the 
transcription factor NFκB which can activate many pro-




. This indicates that 
genetically determined low NFκB activity, and thus low 
activity of other pro-inflammatory pathways, was associated 
with beneficial response.  
rs4612666 Apoptosis CT or TT 0.63 (0.44-0.91) 0.01 rs4612666T reduce expression 
a
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vs CC in THP-1 cells 
41
response. NLRP3 is involved in the inflammasome complex 




. Anti-TNF can induce apoptosis 
3-5
Inflammatory bowel disea se (IBD)  
 and it could 
be speculated, that anti-TNF has a better effect among 
patients, whose pro-inflammatory secreting cells are 
genetically determined more prone for programmed cell 
death. 
TLR4  rs5030728 Pathogen 
recognition 




Same as for UC.  
TLR4  rs1554973 Pathogen 
recognition 
TC or CC 
vs TT 




Same as for UC.  
NFKBIA  rs696 Pathogen 
recognition 
GA or AA 
vs GG 
1.25 (1.01-1.54) 0.04 2758A increase expression in 





Same as for UC. 
 
IL1RN  rs4251961 Cytokines TC or CC 
vs TT 
0.81 (0.66-1.00) 0.049 rs4251961C reduce IL-1RA level 





Reduced IL-1 receptor antagonist (IL-1RA) level was 
associated with non-response. IL-1RA can bind to the IL-1β 
receptor and thereby inhibit IL-1β signaling  45
IL6 
. This indicates 
that genetically determined high IL-1β-driven inflammatory 
response was associated with non-response. 
rs10499563 Cytokines CT or CC 
vs TT 





Reduced IL-6 expression was borderline associated with 
beneficial response. This indicates that genetically 
determined high IL6-driven inflammatory response was 
associated with non-response. 
 
IL18 rs1946518 Cytokines GT or TT 
vs GG 





 and expression in 
PBMC 
35
Reduced IL-18 expression was associated with beneficial 
response. This indicates that genetically determined high 
IL18-driven inflammatory response was associated with non-
response. 
 
NLRP3  rs4612666 Apoptosis CT or TT 
vs CC 
0.73 (0.57-0.95) 0.02 rs4612666T reduce expression 




Same as for UC.  
 
JAK2 rs12343867 Cytokines TC or CC 
vs TT 
1.24 (1.01-1.53) 0.04 rs12343867C reduce expression 




Same as for CD.  
 
PBMC: peripheral blood mononuclear cell. 
a
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b
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Table 3:  Odds ratio (OR), 95% confidence interval (95% CI), sensitivity, specificity, positive (PPV) and negative predictive value (NPV) 
for the risk sum (number of alleles) of the three single nucleotide polymorphisms associated with drug response in Crohns disease in 






















5 (N = 17) 16 1 1 -  - - 94 6 
4 (N =75) 59 16 4.34 (0.53-35.24) 0.18 98 0 79 21 
3 (N = 223) 166 57 5.49 (0.71-42.36) 0.08 90 6 74 26 
2 (N = 305) 215 90 6.70 (0.88-51.27) 0.049 68 24 70 30 
1 (N = 294) 202 92 7.29 (0.95-55.78) 0.028 40 53 69 31 
0 (N = 154) 102 52 8.16 (1.05-63.22) 0.024 13 83 66 34 
a
The risk sum was calculated by summarising the number of risk alleles for the three SNPs associated with drug response in Crohns 

























































Table 4:  Odds ratio (OR), 95% confidence interval (95% CI), sensitivity, specificity, positive (PPV) and negative predictive value (NPV) 























8 (N = 12) 3 9 1 - - - - 25 75 
7 (N = 42) 18 24 2.25 (0.53-9.52) 0.33 99 4 43 57 
6 (N = 88) 49 39 3.77 (0.96-14.87) 0.064 95 13 56 44 
5 (N = 151) 90 61 4.43 (1.15-17.01) 0.031 85 28 60 40 
4 (N =180) 122 58 6.31 (1.65-24.19) 0.0042 65 52 68 32 
3 (N = 136) 98 38 7.74 (1.99-30.12) 0.0017 39 75 72 28 
2 (N = 66) 46 20 6.90 (1.69-28.21) 0.0048 17 90 70 30 
1 (N = 30) 25 5 15.00 (2.96-75.91) 0.00063 7 98 83 17 
0 (N = 9) 8 1 24.00 (2.06-279.64) 0.0075 2 100 89 11 
a
The risk sum was calculated by summarising the number of risk alleles for the five SNPs associated with drug response in ulcerative 
colitis (TLR2, rs11938228 (CC=0; AC=1; AA=2), TLR4, rs5030728 (GG=2; GA=1; AA=0), TLR4, rs1554973 (TT=0; TC=1; CC=2), 
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2,191 patients from 23 medical departments 
had ICD-10 codes of K50-K63 and their 
patient records were examined.  
Excluded 
Data from 682 patients were not registed 
because of missing data or no confirmed CD 
or UC diagnosis. 
Eligibility 
834 CD and 675 UC patients with 
inflammatory bowel diseases were 
registered. 
Excluded  
247 CD and 217 UC patients were not 
treated with anti-TNF. 
 
Samples 
In the inclusion period 44,224 blood samples 
were collected from 24,596 patients.  
 
Excluded 
20,551 patients did not have ICD-10 codes 
of K50-K63. 
Inclusion period 
Blood samples sent from the Danish hospitals for Mycobacterium tuberculosis screening were 
collected from 01.09.2009 to 31.01.2014. 
Identification 
4,045 patients had ICD-10 codes of K50-
K63. 
Excluded 
1,854 patients were from other departments 
than the department of medicine or from 































587 CD and 458 UC patients were treated with anti-TNF. The patients had not previously been 
treated with anti-TNF. 
Response was achieved by 69% (406) and 65% (296) of the patients with CD and UC respectively.  
Non- or partial-response was achived by 31% (181) and 35% (162) of the patients with CD and UC, 









































































































































Figure 3: Simplified overview of the pathways assessed. 
Polymorphisms in genes associated or not associated with response to anti-TNF therapy among 
patients with Crohn's disease or ulcerative colitis are written in white and red, respectively. Genes 
not studied are written in black. 
Green: Increased gene/protein activity was associated with beneficial response  
Purple: Increased gene/protein activity was as ociated with non-response. 
Blue: The biological effect was unknown. 
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